Cimerli Interchangeable Biosimilar Approved Without Switching Data

Coherus Ranibizumab Rival Will Compete With Lucentis And Byooviz In US

 
• By Sue Sutter
  
Railroad tracks crossing
Coherus avoided having to conduct a study in which patients switched back and forth between Cimerli and the reference product Lucentis • Source: Shutterstock

More from Products

More from Generics Bulletin